Qnovia Inc, a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its inhaled drug delivery platform, the RespiRx, announced the first patient was dosed in its phase 1 clinical trial evaluating RespiRx Nicotine Inhaler (QN-01) as a smoking cessation therapy in the US
- It is necessary to get moral and psychological support from his family, friends and those around him
If you want to know more about a specific drug, you can search the FDA's Drugs@FDA website, which includes information on each product by name
Kenny is in the Nash Family Department of Neuroscience and the Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA